Pulling SEC filings + quote and writing the call…

ChronoScale Corp
Next earnings Jul 27, 2026 · consensus $-0.06 EPS, $2.55M rev
Last earnings +13.0% on 2026-02-17
Cash-burning exoskeleton micro-cap with collapsing revenue, $1.2M cash against $11.8M annual burn — going-concern math doesn't work.
ChronoScale (operating as an exoskeleton maker — EksoNR, Ekso Indego, EVO) is in acute financial distress masquerading as a turnaround story. FY2025 revenue collapsed 29% to $12.8M — and crucially, the MD&A attributes this to a drop in Enterprise Health device volume in EMEA, the company's core revenue engine, only partially offset by Personal Health gains. The CMS reimbursement narrative for Ekso Indego Personal (approved April 2024 at ~$91,000) is the bull case, but two years in it has not arrested the top-line decline. Gross margin held at 53%, which is the only fundamental positive here.
Sources: SEC EDGAR (CIK 0001549084, latest 10-Q filed 2026-04-28) · EODHD · analysis by claude-code · as of 6/25/2026, 1:46:49 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $11.2M | $12.9M | $18.3M | $17.9M | $12.8M |
| Gross profit | $6.75M | $6.21M | $9.08M | $9.51M | $6.84M |
| Operating income | -$13.8M | -$15.6M | -$15.1M | -$10.5M | -$13.3M |
| Net income | -$9.76M | -$15.1M | -$15.2M | -$11.3M | -$11.7M |
| Diluted EPS | -$0.88 | -$1.16 | -$1.10 | -$8.43 | -$4.91 |
| Net margin | -86.8% | -116.8% | -83.1% | -63.2% | -91.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosed material exit/disposal charges — restructuring as cash runway tightens
Amendment refining details of the May 4 financing/charter disclosure
Amendment correcting/supplementing prior 8-K disclosure — administrative
New financing deal with unregistered share issuance and charter amendment — dilutive
Q1 2026 results — continued losses with cash at $1.2M raising going-concern pressure
Amended FY2025 10-K — restatement/cleanup signals controls or disclosure issues
FY2025 revenue -29% to $12.8M, -$11.7M loss, cash down 74% to $1.2M
Change-of-control event with board shakeup, equity issuance and Q4 results disclosed
1049 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-05-14 | CLANCY WILLIAM M Director | Award | 200K | |
| 2026-05-14 | Cummins Wes Director | Award | 200K | |
| 2026-05-14 | Benson Ella G. Director | Award | 200K | |
| 2026-05-14 | Wong Jerome Chief Financial Officer | Award | 40.0K | |
| 2026-05-14 | Nottenburg Richard N Director | Award | 200K | |
| 2026-05-14 | MILLER DOUGLAS S Director | Award | 200K | |
| 2026-05-14 | Davis Scott G. Director | Award | 109K | |
| 2026-03-16 | Jones Jason C Chief Operating Officer | Buy | 1.31K @ $11.85 | $15.5K |